Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
NCT06552234Phase 2Recruiting
- Sponsor
- Centre Hospitalier Intercommunal de Toulon-La Seyne-sur-Mer
- Start
- Oct 2024
- Primary completion
- Sep 2031
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of repotrectinib in non-small cell lung cancer (NSCLC), sponsored by Centre Hospitalier Intercommunal de Toulon-La Seyne-sur-Mer. Started Oct 2024; status: recruiting.
02
Drugs
repotrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06552234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552234.